Dikla Czaczkes Akselbrad

2 weeks ago | en.globes.co.il | Dikla Czaczkes Akselbrad |Gali Weinreb

The Israeli company's treatment is a delayed-release antibiotic administered in the area where the patient has undergone surgery. Israeli late-stage biopharmaceutical company PolyPid (Nasdaq: PYPD) has reported positive Phase III trial results on its treatment for surgical infections. In 2022, PolyPid's previous trial of the drug failed, which saw its share price fall 77% in one day and continue falling since. Yesterday the share price rose 2.75%, giving a market cap of $34.24 million.

1 month ago | infectioncontroltoday.com | Tori Whitacre Martonicz |Dikla Czaczkes Akselbrad

As surgical site infections (SSIs) begin to rise again across health care systems, traditional prevention strategies are being tested and often found wanting. Dikla Czaczkes Akselbrad, the chief executive officer of PolyPid, believes it is time for a paradigm shift. In a candid interview with Infection Control Today®(ICT®), Akselbrad outlines the critical role localized drug delivery can play in closing the gap between perioperative protocols and real-world outcomes.